Trajan Completes Integration of SGE Analytical Science

Trajan Completes Integration of SGE Analytical Science

June 26, 2014

Melbourne, Australia: Trajan Scientific and Medical (Trajan) will complete the integration of SGE Analytical Science (SGE) at all major operational centers in Australia, Europe, the US and Asia, as of July 1, 2014, when SGE entities will register new Trajan business names.

For workers in many laboratories around the world, SGE is synonymous with the highest quality in chromatography components and consumables. The company has established a leading reputation over the last 50 years. The SGE brand will live on and continue to grow in this field, supported by Trajan and its well-established network of distributors.

Stephen Tomisich, Trajan's Chief Executive Officer said, "We are proud to build on the strong foundations of SGE as one of our trusted brands."

Trajan's focus is on developing and commercializing technologies that enable analytical systems to be more selective, sensitive and specific for biological, environmental or food related measurements, particularly those that lead to portability, miniaturization and affordability.

"Our growth plans will see us enter a number of new fields, beyond the traditional SGE chromatography landscape, over the coming year. Trajan is now in a position to strengthen existing partnerships and forge new ones on our journey towards personalized measurement, meaningful analysis for point-of-care diagnostics and environmental monitoring" said Mr Tomisich.

Trajan's Chief Scientific Officer, Dr Andrew Gooley, believes that by fully integrating SGE into Trajan, it will enable the company to make the most of SGE's capabilities and work more effectively with industry, academic and government partners to develop new technologies for human and environmental wellbeing.

"We are very excited to undertake new projects beyond our established analytical chemistry product portfolios. The company's expertise in miniaturized glass and metal fabrication, chemistry platforms, precision scientific tubing and micro fluidic components and connections will make a major contribution both to our partners and to end-users." said Dr Gooley.

Trajan, formed in 2011, has a global presence with around 300 staff worldwide, with headquarters in Melbourne, Australia and significant operations in the USA, Europe and Japan.

Contact Information
Email: media@trajanscimed.com

For press information, please contact:
Richard Kent
Director, Kapler Communications
Tel: +44 (0)1480 471059 (United Kingdom)
Email: richard.kent@kapleronline.com
Kapler Communications




Also in News

Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst

September 07, 2020

Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.

Read More

European patent for Trajan’s hemaPEN
European patent for Trajan’s hemaPEN

July 13, 2020

Trajan Scientific and Medical is proud to advise that the European Patent Office will be granting a patent for hemaPEN® as a liquid collection device in Belgium, France, Germany, Ireland, Luxembourg, Monaco, Switzerland, Liechtenstein and the United Kingdom. Extensions are being sought across the remainder of Europe.

Read More

US FDA listing of Trajan’s hemaPEN blood microsampling device
US FDA listing of Trajan’s hemaPEN blood microsampling device

July 02, 2020

Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.

Read More